TRS-02 developed as an anti-inflammatory TRS formulation for back-of-eye diseases
Aug. 16, 2022
Tarsier Pharma is developing the small molecule TRS as an anti-inflammatory treatment for retinal diseases, with the eye drop formulation TRS-01 in phase III development for noninfectious anterior uveitis and uveitic glaucoma.